PRESS RELEASE
First-half financial information at June 30, 2024
IFRS – Regulated information – Audited
Cegedim: Revenue and EBITDA both increased in the first half of 2024
Revenue grew 6.0% as reported and 4.6% LFL to €319.0 millionEBITDA rose 6.9% to €52.2 millionRecurring operating income(1) (REBIT) fell 3.4% to €10.3 million
Boulogne-Billancourt, France, September 26, 2024, after the market close
Cegedim generated consolidated H1 2024 revenues of €319.0 million, a 6.0% year-on-year increase as reported, and EBITDA of €52.2 million, a €3.4 million or 6.9% increase. Recurring operating income fell €0.4 million, or 3.4%, to €10.3 million.
H1 2024H1 2023Change in €m(in %)(in €m)(in %)(in €m)in %Revenues319.0100.0%301.0100.00%18.06.0%EBITDA(1)52.216.4%48.8+16.2%3.46.9%Depreciation & amortization-41.9 -38.1 -3.8-9.8%Recurring operating income(1)10.33.2%10.73.6%-0.4-3.4%Other non-recurring operating income and expenses(1)-2.6 -1.4 -1.2-88.8%Operating income7.72.4%9.33.1%-1.6-17.1%Financial result-5.0 -5.6 0.610.8%Total tax-2.9 -12.4 9.576.8%Share of net profit (loss) of equity method companies0.1 -0.5 0.6110.3%Consolidated net profit-0.10.0%-9.2-3.1%9.199.0%Non-controlling interests-0.7 -0.4 -0.3-69.3%Group share0.60.2%-8.8-2.9%9.4107.2%Recurring earnings per share(2) (in euros)0.0–-0.6– Earnings per share (in euros)0.0–-0.6–
Consolidated revenues rose €18.0 million, or 6.0%, to €319.0 million in H1 2024 compared with €301.0 million in 2023. The positive scope effect of €3.7 million, or 1.2%, was attributable to the first-time consolidation in Cegedim’s accounts of Visiodent starting March 1, 2024. The positive currency impact was €0.5 million, or 0.2%, chiefly owing to appreciation of the pound sterling against the euro. In like-for-like terms(2), revenues rose 4.6% in the first half, in line with the Group’s announced outlook. The performance was attributable to seasonality and the non-recurrence of Ségur public health investments in 2024.
EBITDA(1) rose €3.4 million between the first half of 2023 and 2024, or 6.9%. The improvement is the result of good management of personnel costs and external costs, in moderate growth as a percentage of revenues even though the amount of R&D capitalization fell and the Group had an additional quarter of start-up costs for its biggest BPO contract.
————-
(1) Alternative performance indicator See pages 112-113 of the 2023 Universal Registration Document.
(2) At constant scope and exchange rates.
Depreciation and amortization expenses rose €3.7 million, chiefly due to a €3.1 million increase in R&D amortization (€22.7 million at June 30, 2024 compared with €19.7 million a year earlier) driven by development efforts in recent years.
Recurring operating income(1) fell €0.4 million to €10.3 million in H1 2024 compared with €10.7 million in 2023. It amounted to 3.2% of 2024 revenue compared with 3.6% in 2023. The fine EBITDA performance did not drop through to recurring operating income solely because of higher depreciation and amortization. Excluding the impact of Ségur subsidies and at comparable levels of amortization of capitalized R&D, Recurring operating income would have more than doubled.
Other non-current operating costs(1) amounted to €2.6 million in H1 2024 compared with €1.4 million in the same period in 2023. The principal items in 2024 were restructuring costs related to the Group’s decision to refocus software for doctors in the UK on Scotland and fees related to the Visiodent acquisition.
Taking these elements into account, operating income came to €7.7 million at June 30, 2024, compared with €9.3 million a year earlier.
Financial result was a loss of €5.0 million compared with a €5.6 million loss in H1 2023. Dividend income over the period more than offset the increase in the cost of financial debt.
Tax was back to normal levels at €2.6 million in H1 2024 compared with €12.4 million in H1 2023. As a reminder, in 2023 the Group made a non-cash adjustment that caused it to record a deferred tax charge corresponding to the downward revision of its estimated remaining deferred tax assets.
Analysis of business trends by division
in millions of eurosTotalSoftware & ServicesFlowData & MarketingBPOCloud & SupportRevenue 2023 reported
2023 reclassified (*)301.0
301.0161.5
150.648.2
46.854.9
54.932.8
32.83.5
15.82024319.0152.149.559.339.918.1Change6.0%1.0%5.8%8.0%21.6%14.5% Recurring operating income 2023 reported
2023 reclassified (*)10.7
10.7-2.0
-2.55.6
5.26.6
6.61.4
1.4-0.9
0.0202410.3-1.45.95.31.9-1.3Change-3.4%42.4%12.8%-19.8%36.0%na Recurring operating margin (as a % of revenues)
2023 reported
3.6%
-1.2%
11.7%
11.9%
4.3%
-24.7%2023 reclassified (*)3.6%-1.7%11.1%11.9%4.3%0.3%20243.2%-1.0%+11.8%8.9%4.8%-7.0%
(*) As of January 1, 2024, our Cegedim Outsourcing and Audiprint subsidiaries—which were previously housed in the Software & Services division—as well as BSV—formerly of the Flow division—have been moved to the Cloud & Support division in order to capitalize on operating synergies between cloud activities and IT solutions integration.
Software & Services: H1 2024 revenues posted a €1.5 million increase, and recurring operating income (REBIT)(1) improved by €1.1 million to a loss of €1.4 million, compared with a €2.5 million loss a year earlier.
————-
(1) Alternative performance indicator See pages 112-113 of the 2023 Universal Registration Document.
Software & ServicesFirst halfChange
2024 / 2023
in millions of euros20242023Revenues152.1150.61.51.0%Cegedim Santé38.939.8-1.0-2.4%Insurance, HR, Pharmacies, and other services86.784.52.32.7%International businesses26.526.30.20.6%Recurring operating income(1)-1.4-2.51.142.4%Cegedim Santé-1.6-1.4-0.2-11.8%Insurance, HR, Pharmacies, and other services3.43.30.13.5%International businesses-3.3-4.41.125.6%
As expected, Cegedim Santé felt the impact of increased R&D amortization (nearly €1 million) and a demanding comparison owing to the non-recurrence of Ségur public health investments (€4.4 million in H1 2023 revenues). The consolidation of Visiodent starting March 1, 2024, only partly offset those two items. Recurring operating income was nearly stable over the first half, but EBITDA increased as expected.
The other businesses in the division posted REBIT(1) of €1.2 million. A solid performance by HR solutions, which managed to keep costs under control during a phase of strong growth, compensated for slower pharmacy equipment sales post-Ségur. The international businesses got a boost from dynamic sales for doctors in Spain and for insurers in the UK. As we shift our operations, narrowing the focus of our UK doctor’s software business to Scotland continued to generate costs in the first half.
Flow: Revenues rose 5.8%, driven by Cegedim e-business (process digitalization and electronic data flows), both of whose businesses made positive contributions; by Invoicing & Procurement, which rebounded in France and is benefiting from the upcoming reform in Germany; and by Healthcare Flow Management, which has dynamic new offerings for hospitals to make their drug purchasing secure. Over the same period, Third-party payer systems posted 3.6% growth. As a result, REBIT(1) rose 12.8%, with Third-party payer systems making the biggest contribution, as Cegedim e-business recorded a large R&D amortization charge.Data & Marketing: Trends differed at this division—Marketing is still going strong, with 20% growth, whereas Data revenues fell 2.8%, particularly abroad. REBIT(1) of €6.6 million was down €1.3 million over the first half owing to high fixed costs in Data and increased depreciation and amortization costs at C-Media (+€1 million) due to heavy investments in updating its digital signage equipment.BPO: Revenue jumped more than 21% over the first half, buoyed notably by a full six months of the contract with Allianz, which started on April 1, 2023, and is expected to generate losses in the early years. But the division reined in those losses so well that REBIT(1) rose €0.5 million in the first half of 2024 to reach €1.9 million, also getting a boost from the HR BPO and digitalization businesses.Cloud & Support: H1 2024 REBIT(1) was a loss of €1.3 million, compared with breakeven a year earlier. The drop was due to surcharges related to the launch of a new cloud offering and recruitment of new offshore teams.
———
(1) Alternative performance indicator See pages 112-113 of the 2023 Universal Registration Document.
Highlights
Apart from the items cited below, to the best of the company’s knowledge, there were no events or changes during H1 2024 that would materially alter the Group’s financial situation.
Acquisition of Visiodent
On February 15, 2024, Cegedim Santé acquired Visiodent, a leading French publisher of management software for dental practices and health clinics. Visiodent launched the market’s first 100% SaaS solution, Veasy, at a time when it was significantly expanding its organization. Its users now include the country’s largest nation-wide networks of health clinics, both cooperative and privately owned, as well as several thousand dental surgeons in private practice. Visiodent generated revenue of c.€10 million in 2023 and began contributing to Cegedim Group’s consolidation scope on March 1, 2024.
Tax
Cegedim S.A. has been subject to two tax audits since 2018, which have resulted in reassessments relating to the use of tax-loss carryforwards contested by the tax authorities. Cegedim, in consultation with its lawyers, believes that the reassessments are unfounded in light of the applicable tax law and jurisprudence. The Company has therefore taken, and continues to take, all possible avenues of contestation.
As these appeals are not suspensive, Cegedim has paid the amounts reassessed over time (a total of 23 million euros already paid, including 10.9 million euros disbursed in February 2024). The remaining risk of future disbursements in respect of this dispute thus amounts to only 5 million euros at June 30, 2024.
However, these disbursements have never given rise to the recognition of a tax charge in the P&L, since the Company considers that these sums will be recoverable at the end of the proceedings (they are recognized as advances paid on the assets side of the balance sheet). Should the outcome be unfavorable, a charge of 28 million euros (of which 23 million has already been paid) would have to be recorded in the consolidated income statement.
In addition, the consolidated balance sheet must show the future tax savings still realizable in respect of tax loss carryforwards. This “deferred tax asset” amounted to 6.9 million euros at June 30, 2024.
Should the outcome be unfavorable, the probability of realizing these future savings would become nil, and an adjustment of 6.9 million euros would have to be recorded in the consolidated income statement (with no cash impact, since these gains have never yet been realized).
Consequently, the risk associated with this dispute is not (or very little) in terms of cash, but rather in terms of a possible adjustment to the consolidated income. The maximum P&L adjustment risk is known: it amounts to 34.9 million euros and will remain unchanged. Only its breakdown varies at each closing: the amount of disputed tax savings (28 million to date) will continue to increase, and that of remaining future savings (6.9 million to date) will decrease accordingly until exhausted.
In the last quarter of 2023, the Company referred this dispute to the administrative court, which is likely to continue for several years.
Significant transactions and events post June 30, 2024
Apart from the items cited below, to the best of the company’s knowledge, there were no post-closing events or changes after June 30, 2024, that would materially alter the Group’s financial situation.
New financing arrangement
On July 31, 2024, Cegedim announced that it had secured a new financing arrangement consisting of a €230 million syndicated loan. The arrangement is split into €180 million of lines drawn upon closing to refinance the Group’s existing debt (RCF and Euro PP, which were to mature in October 2024 and October 2025 respectively) and an additional, undrawn revolving credit facility (RCF) of €50 million. This new financing arrangement will bolster the Group’s liquidity and extend the maturity of its debt to, respectively, 5 years (€30 million, payments every six months); 6 years (€60 million, repayable upon maturity); and 7 years (€90 million, repayable upon maturity).
Outlook
Based on the currently available information, the Group expects 2024 like-for-like(2) revenue growth to be in the range of 5-8% relative to 2023. Recurring operating income should continue to improve, following a similar trajectory as in 2023.
Recurring operating income(1) is expected to grow, notably thanks to the initial returns on investments made in Cegedim Santé and refocusing international activities.
These targets may need to be revised in the event of unexpected developments (pandemic, etc.) and/or a significant worsening of geopolitical and macroeconomic risks. The Group reiterates that it has no activities or exposed assets in Russia or Ukraine.
—————
The Audit Committee met on September 25, 2024. The Board of Directors, chaired by Jean-Claude Labrune, met on September 26, 2024, and approved the consolidated financial statements at June 30, 2024, of which the statutory auditors have conducted a limited review. The Interim Financial Report will be available in a few days’ time, in French and in English, on our website.
WEBCAST ON SEPTEMBER 26, 2024, AT 6:15 PM (PARIS TIME) The webcast is available at: www.cegedim.fr/webcast
The first-half 2024 results presentation is available: On the website: https://www.cegedim.fr/finance/documentation/Pages/presentations.aspx
2024 financial calendar
2024October 24 after the closeQ3 2024 revenues
Financial calendar: https://www.cegedim.fr/finance/agenda/Pages/default.aspx
Disclaimer
This press release is available in French and in English. In the event of any difference between the two versions, the original French version takes precedence. This press release may contain inside information. It was sent to Cegedim’s authorized distributor on September 26, 2024, no earlier than 5:45 pm Paris time.
The figures cited in this press release include guidance on Cegedim’s future financial performance targets. This forward-looking information is based on the opinions and assumptions of the Group’s senior management at the time this press release is issued and naturally entails risks and uncertainty. For more information on the risks facing Cegedim, please refer to Chapter 7, “Risk management”, section 7.2, “Risk factors and insurance”, and Chapter 3, “Overview of the financial year”, section 3.6, “Outlook”, of the 2023 Universal Registration Document filled with the AMF on April 3, 2024, under number D.24-0233.
About Cegedim:
Founded in 1969, Cegedim is an innovative technology and services group in the field of digital data flow management for healthcare ecosystems and B2B, and a business software publisher for healthcare and insurance professionals. Cegedim employs more than 6,500 people in more than 10 countries and generated revenue of €616 million in 2023.
Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more please visit: www.cegedim.fr
And follow Cegedim on X: @CegedimGroup, LinkedIn, and Facebook.
Aude Balleydier
Cegedim
Media Relations
and Communications Manager
Tel.: +33 (0)1 49 09 68 81
aude.balleydier@cegedim.frDamien Buffet
Cegedim
Head of Financial Communication
Tel.: +33 (0)7 64 63 55 73
damien.buffet@cegedim.comCéline Pardo
Becoming RP Agency
Media Relations Consultant
Tel.: +33 (0)6 52 08 13 66
cegedim@becoming-group.com
———
(1) Alternative performance indicator See pages 112-113 of the 2023 Universal Registration Document.
(2) At constant scope and exchange rates.
Annexes
Consolidated financial statements at June 30, 2024
Assets au 30 juin 2024 In thousands of euros6/30/202412/31/2023Goodwill 234,955199,787Development costs29,7061,562Other intangible fixed assets177,834192,616Intangible non-current assets207,541194,178Land594544Buildings1,5561,660Other property, plant, and equipment53,00645,829Advances and non-current assets in progress901831Rights of use86,09289,718Tangible fixed assets142,149138,582Equity investments00Loans16,33215,332Other long-term investments7,1205,230Long-term investments – excluding equity shares in equity method companies23,45220,563Equity shares in equity method companies19,08622,065Deferred tax assets18,20919,747Prepaid expenses: long-term portion00Non-current assets645,390594,922Goods6,0725,498Advances and deposits received on orders1,3963,703Accounts receivables: short-term portion182,907175,199Other receivables: short-term portion59,07059,563Current tax credits27,26216,495Cash equivalents00Cash35,41446,606Prepaid expenses: short-term portion26,13822,082Current assets338,260329,146Total assets983,651924,068 Liabilities et shareholders’ equity at June 30, 2024 In thousands of euros6/30/202412/31/2023Share capital 13,43213,337Consolidated retained earnings276,449282,521Group exchange gains/losses-11,848-12,275Group earnings630-7,407Shareholders’ equity, Group share278,663276,175Minority interest17,55018,381Shareholders’ equity296,213294,556Non-current financial liabilities187,714188,546Non-current lease liabilities76,26778,761Deferred tax liabilities5,9495,600Post-employment benefit obligations30,63231,007Non-current provisions2,1472,521Non-current liabilities302,710306,435Current financial liabilities61,5703,006Current lease liabilities 14,66114,789Trade payables and related accounts57,22561,734Current tax liabilities192235Tax and social security liabilities 113,884121,371Non-current provisions1,6601,730Other current liabilities135,538120,212Current liabilities384,728323,077Total liabilities983,651924,068 Income statement at June 30, 2024 In thousands of euros6/30/20246/30/2023Revenues 318,995301,011Purchases used-14,045-14,739External expenses-72,687-66,371Taxes-3,961-4,291Payroll costs-173,240-163,623Impairment of trade receivables and other receivables and on contract assets-872-2,041Allowances to and reversals of provisions -2,440-1,830Other operating expenses-690108Share of profit (loss) from affiliates on the income statement1,146603EBITDA (1)52,20748,827Depreciation expenses other than right-of-use assets -33,140-29,030Depreciation expenses of right-of-use assets-8,733-9,097Recurring operating income(1)10,33410,700Non-recurring operating income and expenses-2,616-1,385Other non-recurring operating income and expenses(1)-2,616-1,385Operating income7,7189,315Income from cash and cash equivalents 326 180Cost of gross financial debt-7,121 -5,633Other financial income and expenses 1,813 -136Net financial income (expense)-4,983-5,589Income taxes-1,226-1,841Deferred income taxes-1,652-10,588Tax-2,878-12,429Share of profit (loss) from affiliates 53-515Consolidated net profit-90-9,219Group share 630-8,793Income from equity-accounted affiliates-721-426Average number of shares excluding treasury stock13,695,31713,658,348Recurring earnings per share (in euros)0.0-0.6Earnings per share (in euros)0.0-0.6 Cash flow statement as of June 30, 2024 In thousands of euros6/30/20246/30/2023Consolidated net profit-90-9,219Share of profit (loss) from affiliates-1,199-88Depreciation and amortization expenses and provisions 40,53137,972Capital gains or losses on disposals of operating assets -52-798Cash flow after cost of net financial debt and taxes39,19027,867Cost of net financial debt4,9835,589Tax expenses2,87812,429Cash flow from operating activities before tax and interest47,05145,885Tax paid-11,634-378Impact of change in working capital requirements-13,206-18,032Cash flow generated from operating activities after tax paid and change in
working capital requirements 22,21127,476Acquisitions of intangible fixed assets-29,879-29,550Acquisitions of tangible fixed assets-15,935-11,759Acquisitions of long-term investments0-36Disposals of property, plant, and equipment and of intangible assets5532,575Disposals of long-term investments934805Change in deposits received or paid-860-156Impact of changes in consolidation scope-35,454-2,172Dividends received from outside the Group4,07330Net cash from (used in) investing activities -76,568-40,264Capital increase985-Dividends paid to minority shareholders of consolidated cos.0-Dividends paid to shareholders of the parent company-1-Debt issuance55,000-Debt repayments-219-193Employee profit sharing 145129Repayment of lease liabilities-8,152-11,353Interest paid on loans-972-117Other financial income received718596Other financial expenses paid -3,612-3,492Net cash flow used in financing activities 43,892-14,430Change in net cash excluding currency impact -10,465-27,218Impact of changes in foreign currency exchange rates-728-456Change in net cash -11,194-27,674Opening cash46,60655,553Closing cash35,41227,879 Financial covenants
The Group complied with all its covenants as of June 30, 2024.
(1) Alternative performance indicator
Attachment
